Yu-Duan T, Chao-Ping
W, Chih-Yu C, Li-Wen L, Tsun-Mei L, Chia-Chang H, Fu-Mei C, Hsien-Chang L, Hsia-Fen H, Yau-Jiunn L, Jer-Yiing
H. Elevated plasma level of visfatin/pre-b
cell colony-enhancing factor
in male oral squamous cell carcinoma patients. Med Oral
Patol Oral Cir Bucal. 2013 Mar 1;18
(2):e180-6.
doi:10.4317/medoral.18574
http://dx.doi.org/doi:10.4317/medoral.18574
|
1. Bagan
J, Sarrion G, Jimenez Y.
Oral cancer: clinical features. Oral Oncol. 2010;46:414-7. |
|
|
|
|
|
2. Cancela Mde C, Ramadas K, Fayette JM, Thomas G, Muwonge
R, Chapuis F, et al. Alcohol intake and oral cavity
cancer risk among men in a prospective study in Kerala, India. Community Dent
Oral Epidemiol. 2009;37:342-9. |
|
|
|
|
|
3. Chen PC, Kuo C, Pan CC, Chou MY. Risk of
oral cancer associated with human papillomavirus
infection, betel quid chewing, and cigarette smoking in Taiwan–an integrated
molecular and epidemiological study of 58 cases. J Oral Pathol
Med. 2002;31:317-22. |
|
|
|
|
|
4. Jayalekshmi PA, Gangadharan
P, Akiba S, Nair RR, Tsuji M, Rajan
B. Tobacco chewing and female oral cavity cancer risk in Karunagappally
cohort, India. Br J Cancer.
2009;100:848-52. |
|
|
|
|
|
5. Machon C, Thezenas
S, Dupuy AM, Assenat E,
Michel F, Mas E, et al. Immunonutrition
before and during radiochemotherapy: improvement of
inflammatory parameters in head and neck cancer patients. Support Care Cancer.
2012;20:3129-35. |
|
|
|
|
|
6. Coussens LM, Werb
Z. Inflammation and cancer. Nature. 2002;420:860-7. |
|
|
|
|
|
7. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436-44. |
|
|
|
|
|
8. Nakajima
TE, Yamada Y, Hamano T, Furuta K, Gotoda T, Katai H, et al. Adipocytokine levels in
gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol. 2009;44:685-90. |
|
|
|
|
|
9. Wu
MH, Chou YC, Chou WY, Hsu GC, Chu CH, Yu CP, et al. Circulating levels of leptin,
adiposity and breast cancer risk. British Journal of Cancer. 2009;100:578-82. |
|
|
|
|
|
10. Gonullu G, Kahraman
H, Bedir A, Bektas A, Yücel I. Association between adiponectin,
resistin, insulin resistance, and colorectal
tumors. Int J Colorectal Dis. 2010;25:205-12. |
|
|
|
|
|
11. Sun CA, Wu MH, Chu CH, Chou YC, Hsu GC, Yang T, et al. Adipocytokine resistin and
breast cancer risk. Breast Cancer Res Treat. 2010;123:869-76. |
|
|
|
|
|
12. Howard JM, Pidgeon GP, Reynolds JV. Leptin and gastro-intestinal malignancies. Obes Rev. 2010;11:863-74. |
|
|
|
|
|
13. Bae SK, Kim SR, Kim JG, Kim JY, Koo TH,
Jang HO, et al. Hypoxic induction of human visfatin
gene is directly mediated by hypoxiainducible
factor-1. FEBS Lett.
2006;580:4105-13. |
|
|
|
|
|
14. Gen R, Akbay E, Muslu
N, Sezer K, Cayan F.
Plasma visfatin level in lean women with PCOS:
relation to proinflammatory markers and insulin
resistance. Gynecol Endocrinol. 2009;25:241-5. |
|
|
|
|
|
15. Galli M, Van Gool
F, Rongvaux A, Andris F,
Leo O. The nicotinamide phosphoribosyltransferase:
a molecular link between metabolism, inflammation, and cancer. Cancer Res. 2010;70:8-11. |
|
|
|
|
|
16. Bi TQ, Che XM. Nampt/PBEF/visfatin and cancer. Cancer Biol
Ther. 2010;10:119-25. |
|
|
|
|
|
17. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I.
Cloning and characterization of the cDNA encoding a
novel human pre-B-cell colonyenhancing factor. Mol Cell Biol. 1994;14:1431-7. |
|
|
|
|
|
18. Luk T, Malam
Z, Marshall JC. Pre-B cell colony-enhancing factor (PBEF)/ visfatin: a novel mediator of innate immunity. J Leukoc Biol. 2008;83:804-16. |
|
|
|
|
|
19. Moschen AR, Gerner
RR, Tilg H. Pre-B cell colony enhancing
factor/NAMPT/ visfatin in inflammation and
obesity-related disorders. Curr Pharm
Des. 2010;16:1913-20. |
|
|
|
|
|
20. Moschen AR, Kaser
A, Enrich B, Mosheimer B, Theurl
M, Niederegger H, et al. Visfatin,
an adipocytokine with proinflammatory
and immunomodulating properties. J Immunol. 2007;178:1748-58. |
|
|
|
|
|
21. Jia
SH, Li Y, Parodo J, Kapus
A, Fan L, Rotstein OD, et al. Pre-B cell colonyenhancing factor inhibits neutrophil
apoptosis in experimental inflammation and clinical sepsis. J Clin Invest.
2004;113:1318-27. |
|
|
|
|
|
22. Carrero JJ, Witasp
A, Stenvinkel P, Qureshi
AR, Heimbürger O, Bárány
P, et al. Visfatin is increased in chronic kidney
disease patients with poor appetite and correlates negatively with fasting
serum amino acids and triglyceride levels. Nephrol
Dial Transplant. 2010;25:901-6. |
|
|
|
|
|
23. Greene FL. The American Joint Committee on Cancer: updating the strategies
in cancer staging. Bull Am Coll Surg. 2002;87:13-5. |
|
|
|
|
|
24. Wang CP, Hsu HL, Hung WC, Yu TH, Chen YH, Chiu CA, et al.
Increased epicardial adipose tissue (EAT) volume in
type 2 diabetes mellitus and association with metabolic syndrome and severity
of coronary atherosclerosis. Clin Endocrinol (Oxf). 2009;70:876-82. |
|
|
|
|
|
25. Sommer G, Garten
A, Petzold S, Beck-Sickinger
AG, Blüher M, Stumvoll M,
et al. Visfatin/PBEF/Nampt:
structure, regulation and potential function of a novel adipokine . Clin Sci (Lond).
2008;115:13-23. |
|
|
|
|
|
26. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka
M, Kishimoto K, et al. Visfatin:
a protein secreted by visceral fat that mimics the effects of insulin . Science. 2005;307:426-30. |
|
|
|
|
|
27. Bauer L, Venz S, Junker H, Brandt R, Radons J. Nicotinamide phosphoribosyltransferase and prostaglandin H2 synthase 2 are upregulated in
human pancreatic adenocarcinoma cells after
stimulation with interleukin-1. Int J Oncol. 2009;35:97-107. |
|
|
|
|
|
28. Reddy PS, Umesh S, Thota
B, Tandon A, Pandey P, Hegde AS, et al. PBEF1/ NAmPRTase/Visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value. Cancer Biol Ther.
2008;7:663-8. |
|
|
|
|
|
29. Nakajima
TE, Yamada Y, Hamano T, Furuta K, Matsuda T, Fujita S, et al. Adipocytokines as new promising
markers of colorectal tumors: Adiponectin for
colorectal adenoma and resistin and visfatin for colorectal cancer. Cancer Sci. 2010;101:1286-91. |
|
|
|
|
|
30. Seda CJ, Salas AS,
Sánchez CG, Blasco JM, García IO, Sánchez JM, et al. Thrombocytosis and hematocrit as prognostic factors in renal carcinoma. Arch
Esp Urol. 2011;64:883-90. |
|